[New developments in chemotherapy for experimental brain metastasis].
Numerous animal models of brain tumor have been developed for screening new chemotherapeutic agents effective for brain tumors. However, most of these models have problem (s) of mechanical disruption of the blood-brain barrier by tumor inoculation and/or discrepancy in histologic nature and site of growth between inoculated tumors and human tumors. With the purpose of establishing a better model for the evaluation of antitumor activity, we have developed rat models of leptomeningeal tumors by intralateral-ventricle inoculation of myelogenous leukemia cells (DBLA-6) or AH130 ascites hepatoma cells. It was proved that in the two models there was no disruption of blood-brain barrier function by tumor inoculation and that the histologic pattern of DBLA-6 model tumor closely resembled the diffuse meningeal involvement of leukemic cells seen in the human disease. Using these models, several antitumor agents have been tested and ACNU, CCNU and procarbazine were found to be highly effective when given intravenously or intraperitoneally, and the intralateral-ventricle administration of methotrexate was also found to show a moderate antitumor activity. Furthermore it was found that intraperitoneal administration of spirohydantoin mustard, and intralateral-ventricle administration of 5-fluorodeoxyuridine were highly effective against the AH130 model.
Kobayashi
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005467:Floxuridine / Q000008:administration & dosage; D006827:Hydantoins / Q000008:administration & dosage; D007951:Leukemia, Myeloid / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000473:pathology; D008130:Lomustine / Q000008:administration & dosage; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage; D009368:Neoplasm Transplantation; D015376:Nimustine; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D051381:Rats
D000970:Antineoplastic Agents; D006827:Hydantoins; D009588:Nitrogen Mustard Compounds; D009607:Nitrosourea Compounds; D005467:Floxuridine; D015376:Nimustine; D011344:Procarbazine; D008130:Lomustine; D004317:Doxorubicin; C015511:spiromustine; D008727:Methotrexate; D003630:Daunorubicin